Antiangiogenic Clinical Strategies
Insights into the molecular mechanisms of tumor angiogenesis have led to the identification of potential angiogenic targets and the development of novel antivascular agents. Many of these agents have shown promising antitumor activity. This series of articles examines the advances in our understanding of this complex process and covers topics such as vessel branching morphogenesis, small-molecule and large-molecule therapies, management of adverse effects caused by the antiangiogenic agents and biomarkers of response and resistance.
2009
October 2009 Volume 6 No 10
An overview of small-molecule inhibitors of VEGFR signaling
S. Percy Ivy, Jeannette Y. Wick & Bennett M. Kaufman
doi:10.1038/nrclinonc.2009.130
September 2009 Volume 6 No 9
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Axel Grothey and Evanthia Galanis
doi:10.1038/nrclinonc.2009.110
August 2009 Volume 6 No 8
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen and Jessica N. Cleck
doi:10.1038/nrclinonc.2009.94
June 2009 Volume 6 No 6
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain, Dan G. Duda, Christopher G. Willett, Dushyant V. Sahani, Andrew X. Zhu, Jay S. Loeffler, Tracy T. Batchelor and A. Gregory Sorensen
doi:10.1038/nrclinonc.2009.63
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
Peter Carmeliet, Frederik De Smet, Sonja Loges and Massimiliano Mazzone
doi:10.1038/nrclinonc.2009.64
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
